Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells

Leukemia

Volumn 12, Issue 6, 1998, Pages 845-859

  Drexler, H G ^a  

^a LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

Author keywords

Cyclin; p15; p16; p18; p19; Tumor suppressor genes

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; B CELL LYMPHOMA; CELL CULTURE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CPG ISLAND; DISEASE COURSE; DNA METHYLATION; GENE DELETION; GENE FREQUENCY; HOMOZYGOTE; HUMAN; LEUKEMIA CELL; LYMPHOMA CELL; MULTIGENE FAMILY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE;

EID: 0031860559     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401043     Document Type: Review

References (22)

1. Knudson AG. Mutation and cancer. Adv Cancer Res 1995; 67: 1-23.
2. Levine AJ. Tumor suppressor genes. Bioessays 1990; 12: 60-66.
3. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993; 262: 1980-1981.
4. Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood 1994; 84: 2412-2421.
5. Diaz MO, Ziemin S, Le Beau MM, Pitha P, Smith SO, Chilcote RR, Rowley JD. Homozygous deletion of the alpha and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci USA 1988; 85: 5259-5263.
6. Diaz MO, Rubin CM, Harden A, Ziemin S, Larson RA, Le Beau MM, Rowley JD. Deletions of interferon genes in acute lymphoblastic leukemia. New Engl J Med 1990; 332: 77-82.
7. Aguiar RCT, Sill H, Goldman JM, Cross NCP. The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster. Leukemia 1997; 11: 233-238.
8. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
9. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin dependent kinase-4 inhibitor gene in multiple cancers. Nature 1994; 368: 753-756.
10. Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73: 1059-1065.
11. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
12. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841-854.
13. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 1995; 10: 1061-1067.
14. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE. Rate of p16 (MTS1) mutations in primary tumors with p16 loss. Science 1994; 265: 415-416.
15. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
16. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, De Pinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85: 27-37.
17. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994; 371: 257-261.
18. INK4B-MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994; 8: 2939-2952.
19. Hirai H, Roussel MF, Kato JY, Ashmun R, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995; 15: 2672-2681.
20. INK4. Mol Cell Biol 1995; 15: 2682-2688.
21. Okuda T, Hirai H, Valentine VA, Shurtleff SA, Kidd VJ, Lahti JM, Sherr CJ, Downing JR. Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d, an inhibitor of cyclin D-dependent kinases. Genomics 1995; 29: 623-630.
22. WAF1 mutations and human malignancies. Leuk Lymphoma 1997; 26: 35-41.